INVO Bioscience Inc
NASDAQ:INVO
INVO Bioscience Inc
NASDAQ:INVO
Price:
1.07 USD
-4.46%
Market Closed
Updated:
May 16, 2024
P/E
Price to Earnings
Price to Earnings
-0.3
Current
-1.2
Median
23.9
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-0.3
Market Cap
/
2.6m
Net Income
-8m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
INVO Bioscience Inc
NASDAQ:INVO
|
2.6m USD | -0.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
181.9B USD | 32.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.7B USD | 71.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.5B USD | 37.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.6B USD | 26.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.2B USD | 61.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.4B USD | 56.1 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.7B EUR | 39.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
54.2B USD | 38.3 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
376.2B CNY | 30.9 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
51.4B USD | 80.4 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-4.7
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A
You don't have any saved screeners yet
